Tao-Sheng Chung

Title: Innovations by Tao-Sheng Chung in Cancer Prognosis

Introduction

Tao-Sheng Chung is a notable inventor based in Taipei, Taiwan. He has made significant contributions to the field of cancer research through his innovative inventions. His work focuses on improving the prognosis of cancer radiotherapy, which is crucial for patient treatment and outcomes.

Latest Patents

Tao-Sheng Chung holds a patent for an "Analyzer and analytical method for predicting prognosis of cancer radiotherapy." This invention provides an analyzer that includes a detection device and an arithmetic device. The detection device can identify expression levels of various microRNAs (miRNAs) in a specimen. The miRNAs involved in this analysis include hsa-miR-130a-3p, hsa-miR-215-5p, hsa-miR-29a-3p, hsa-let-7b-5p, hsa-miR-19b-3p, hsa-miR-374a-5p, and hsa-miR-148a-3p. The arithmetic device utilizes logistic regression to analyze these expression levels, allowing for the determination of whether the prognosis of cancer radiotherapy is poor or good. This innovative approach has the potential to enhance treatment strategies for cancer patients.

Career Highlights

Throughout his career, Tao-Sheng Chung has worked at National Central University, where he has contributed to various research projects. His expertise in the field of cancer prognosis has positioned him as a valuable asset in the scientific community.

Collaborations

Tao-Sheng Chung has collaborated with notable colleagues, including Nian-Han Ma and An-Lun Li. Their combined efforts have further advanced research in cancer treatment and prognosis.

Conclusion

Tao-Sheng Chung's innovative work in cancer prognosis through his patented analyzer demonstrates his commitment to improving patient outcomes. His contributions to the field are significant and continue to influence cancer research and treatment methodologies.